Compare STRIDES PHARMA SCIENCE with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs SUN PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE SUN PHARMA STRIDES PHARMA SCIENCE/
SUN PHARMA
 
P/E (TTM) x 13.4 26.0 51.4% View Chart
P/BV x 0.8 2.2 35.2% View Chart
Dividend Yield % 0.6 0.7 86.5%  

Financials

 STRIDES PHARMA SCIENCE   SUN PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
SUN PHARMA
Mar-19
STRIDES PHARMA SCIENCE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147679 169.0%   
Low Rs642375 171.0%   
Sales per share (Unadj.) Rs317.2121.1 261.9%  
Earnings per share (Unadj.) Rs7.813.4 58.6%  
Cash flow per share (Unadj.) Rs25.120.7 121.1%  
Dividends per share (Unadj.) Rs2.002.75 72.7%  
Dividend yield (eoy) %0.20.5 42.9%  
Book value per share (Unadj.) Rs274.3172.6 158.9%  
Shares outstanding (eoy) m89.502,399.26 3.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.4 64.8%   
Avg P/E ratio x114.039.4 289.4%  
P/CF ratio (eoy) x35.725.5 140.1%  
Price / Book Value ratio x3.33.1 106.8%  
Dividend payout %25.520.6 124.0%   
Avg Mkt Cap Rs m80,0581,264,650 6.3%   
No. of employees `0002.517.5 14.3%   
Total wages/salary Rs m4,34159,671 7.3%   
Avg. sales/employee Rs Th11,325.816,608.1 68.2%   
Avg. wages/employee Rs Th1,731.43,409.6 50.8%   
Avg. net profit/employee Rs Th280.11,833.8 15.3%   
INCOME DATA
Net Sales Rs m28,394290,659 9.8%  
Other income Rs m94110,255 9.2%   
Total revenues Rs m29,334300,914 9.7%   
Gross profit Rs m3,96563,076 6.3%  
Depreciation Rs m1,54017,533 8.8%   
Interest Rs m1,9625,553 35.3%   
Profit before tax Rs m1,40350,246 2.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-12,144 3.6%   
Tax Rs m976,009 1.6%   
Profit after tax Rs m70232,093 2.2%  
Gross profit margin %14.021.7 64.4%  
Effective tax rate %6.912.0 58.0%   
Net profit margin %2.511.0 22.4%  
BALANCE SHEET DATA
Current assets Rs m24,836310,692 8.0%   
Current liabilities Rs m18,993173,396 11.0%   
Net working cap to sales %20.647.2 43.6%  
Current ratio x1.31.8 73.0%  
Inventory Days Days7199 71.7%  
Debtors Days Days113112 101.6%  
Net fixed assets Rs m34,289232,477 14.7%   
Share capital Rs m8952,399 37.3%   
"Free" reserves Rs m23,651411,691 5.7%   
Net worth Rs m24,546414,091 5.9%   
Long term debt Rs m15,51315,226 101.9%   
Total assets Rs m65,437646,938 10.1%  
Interest coverage x1.710.0 17.1%   
Debt to equity ratio x0.60 1,718.8%  
Sales to assets ratio x0.40.4 96.6%   
Return on assets %4.15.8 70.0%  
Return on equity %2.97.8 36.9%  
Return on capital %6.910.2 67.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69766,025 23.8%   
Fx outflow Rs m73538,610 1.9%   
Net fx Rs m14,96227,415 54.6%   
CASH FLOW
From Operations Rs m1,87121,965 8.5%  
From Investments Rs m5,826-6,813 -85.5%  
From Financial Activity Rs m-10,157-27,305 37.2%  
Net Cashflow Rs m-2,615-8,442 31.0%  

Share Holding

Indian Promoters % 27.7 63.7 43.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 5.1 736.8%  
FIIs % 8.6 23.0 37.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 8.3 312.0%  
Shareholders   56,241 133,026 42.3%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

What Should You Do in Today's Volatile Markets?(Podcast)

The week gone by was pretty volatile for Dalal street and the global environment is as unpredictable as it can get.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Small Cap Stocks Could Triple in Less than 2 Years... Here's Why(Profit Hunter)

Sep 30, 2019

Historical data backs up my conviction.

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Sep 30, 2019

Select dividend stocks can be very rewarding.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 11, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - IPCA LABS COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS